Pure Global AI
NCT05733715Recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma
Abramson Cancer Center at Penn MedicinePhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Pembrolizumab infusion
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Abramson Cancer Center at Penn Medicine
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 03, 2023
End date
Jan 01, 2028
Enrollment
30 participants
Primary outcome

Change in frequency of progenitor exhausted CD8 T cells (TEX prog) in peripheral blood during neoadjuvant pembrolizumab +/- lenvatinib and in tumor tissue.

Summary

This study will evaluate the effect of investigational drugs, pembrolizumab alone or
 pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given
 before and after surgery to remove kidney cancer.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05733715
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05733715 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abramson Cancer Center at Penn Medicine and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.